Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q1 FY2017 Earnings Presentation
19 slides from Jubilant Pharmova's earnings presentation, Aug 9, 2016
Slide 1: Financial Results Quarter Ended June 30, 2016
Financial Results Quarter Ended June 30, 2016
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : Tuesday, August 09, 2016 Time : 05:00 pm IST Primary Number: +91 22 3938 1071 Secondary Number: +91 22 6746 8354 6000 1221 Available in – Ahmedabad, Bengaluru, Chennai, Cochin, Delhi, Gurgaon, Hyderabad, Kolkata, Noida. Accessible from all major carriers except BSNL/MT
Slide 4: Q1'17 Results Analysis
el pl JUBHANT LIFESCIENCES Q1’17 Results Analysis
Slide 5: Income Statement – Q1'FY17
Income Statement – Q1’FY17 Particulars Q1'FY16 Q1'FY17 YoY Growth (Rs Crs) (%) Total Income from Operations 1,446 1,420 -2% Pharmaceuticals 704 752 7% Life Science Ingredients 718 618 -14% Drug Discovery Solutions 25 50 102% Total Expenditure 1,121 1,051 Other Income 4 4 EBITDA including Other Incom
Slide 6: Reconciliation between Ind-AS and I-GAAP
Reconciliation between Ind-AS and I-GAAP Quarter Ended Year Ended 30th June 31 March 30th June 31 March Particulars (Rs. Crore) (Unaudited) (Unaudited) (Unaudited) (Unaudited) 2016 2016 2015 2016 Net profit as reported earlier under erstwhile IGAAP 159 71 128 431 i) Fair valuation of investments, cl
Slide 7: Financial Highlights – Q1'FY17
Financial Highlights – Q1’FY17 • Consolidated revenue at Rs. 1,420 Crore • Pharmaceutical revenue at Rs. 752 Crore, contributing 53% to the overall mix • LSI revenue at Rs. 618 Crore, contributing 44% to the overall mix • Drug Discovery Solutions revenue at Rs. 50 Crore, contributing 3% to the overa
Slide 8: Pharma Business Highlights – Q1'FY17
Pharma Business Highlights – Q1’FY17 • Revenues of Rs. 752 Crores, rising 7% YoY • Specialty Pharmaceuticals (Sterile Products) revenues grow 13% YoY; contribute 54% to total Pharmaceuticals segment sales • Generics revenues growth was flat during the quarter, with strong growth in our ROW business
Slide 9: Pharma Business Highlights – Q1'FY17
Pharma Business Highlights – Q1’FY17 Region-wise Revenue (Rs crs) Q1'FY16 Q1'FY17 Mix % YoY % ROW India International 665 705 94% 6% 11.2% 6.3% North America 530 501 67% -6% Europe & Japan Europe & Japan 74 119 16% 61% 15.8% ROW 61 84 11% 39% North America India 38 47 6% 23% 66.7% Income from Operat
Slide 10: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Product pipeline as on June 30, 2016 Oral Solids Sterile Products Region Filings Approved Pending Filings Approved Pending US 70 44 26 11 8 3 Canada 22 18 4 14 14 0 Europe 104 101 3 12 10 2 ROW 574 415 159 43 39 4 Total 770 578 192 80 71 9 We have a
Slide 11: Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals
Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals 77 filings of which 69 filings have been approved and 8 filings are pending approval across multiple geographies, including 8 filings in the US with 6 approvals Rubyfill – filing in Canada and Europe i. Rubidium generator
Slide 12: Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals
Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals Orphan Drug I-131 MIBG – NDA filing in US i. Jubilant has received Orphan drug status with eligibility for accelerated approval ii. Indicated for treatment of paediatric Neuroblastoma, accounting for 6% of cancers in childr
Slide 13: Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals
Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals Exametazime (Generic Ceretec) – 505 (b) (2) filing in US i. Approved for brain imaging; Can be utilized for SPECT or Planar Imaging of Infection ii. Submission study report and analysis completed with extremely robust data
Slide 14: Portfolio of Generics – Filings and Approvals
Portfolio of Generics – Filings and Approvals Oral Solids Filed 70 ANDAs in the US i. 44 ANDAs have been approved and 26 ANDAs are pending approval ii. We plan to file 10 ANDAs in FY 17 Made 700 filings in ROW markets including Canada, Europe and Japan i. 534 filings have been approved and 166 f
Slide 15: LSI Business Highlights – Q1'FY17
LSI Business Highlights – Q1’FY17 China and Region-wise Revenue (Rs crs) Q1'FY16 Q1'FY17 Mix % YoY % ROW International 355 296 48% -17% 14.0% Europe, Europe, North America and Japan 232 209 34% -10% North India China and ROW 123 87 14% -29% America and 52.1% Japan India 363 322 52% -11% 33.8% Income
Slide 16: Drug Discovery Solutions Business Highlights – Q1'FY17
Drug Discovery Solutions Business Highlights – Q1’FY17 • Revenues at Rs. 50 Crore, grow 102% YoY; Contributes 3% to total revenues • EBITDA at Rs. 16 Crore, including out-licensing income of US$ 2 Million, up from Rs. (1) Crore in Q1’16 • EBITDA margins at 32.2%, up from -3.5% in Q1’16 • Proprietary
Slide 17: Debt Profile
Debt Profile Particulars 30-Jun-15 31-Mar-16 30-Jun-16 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 90 55 35 Subsidiaries 356 320 287 Total 445 375 322 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,481 1,422 1,522 Subsidiaries 485 626 584 Total 1,966 2,047 2,105 Gross Debt 4,800 4
Slide 18: Outlook
Outlook In FY 2017, maintain momentum going forward led by key initiatives in our key segments • Revenue and profitability growth in Pharmaceuticals segment is expected to be led by: • New product launches in Generics with robust growth in ROW business • Expected launch of Ruby-fill and strong pip
Slide 19: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91-120-436 1002 Ph: +91-22-6645 1209 E-mail: ravi_agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Siddhartha Bhatnagar Jubilant Life Sciences Limited Perfect